SCHEMBL736696

SCHEMBL736696

CSCCn1c(=O)[nH]c2cccc(C)c21

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DAO P14920 2/20 0.53
ALDH1A1 P00352 4/20 0.41
HPGD P15428 4/20 0.41
MAPT P10636 2/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
LMNA P02545 1/20 0.41
TSHR P16473 1/20 0.41
MAPK1 P28482 1/20 0.41
HTT P42858 1/20 0.41
TDP1 Q9NUW8 1/20 0.41
CYP1A2 P05177 2/20 0.40
MEN1 O00255 1/20 0.40
KMT2A Q03164 1/20 0.40
USP2 O75604 1/20 0.35
NPSR1 Q6W5P4 1/20 0.35
MPO P05164 2/20 0.35
AURKA O14965 1/20 0.35
ADORA3 P0DMS8 1/20 0.34
ADORA2A P29274 1/20 0.34
ADORA2B P29275 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL739564 0.79 DAO (0.53) DAOALDH1A1SMN1; SMN2CYP1A2MEN1
SCHEMBL737393 0.77 LMNA (0.68) ALDH1A1HPGDMAPTSMN1; SMN2LMNA
SCHEMBL12431694 0.75 DAO (0.51) DAOALDH1A1HPGDMAPTSMN1; SMN2
SCHEMBL737401 0.75 DAO (0.48) DAOALDH1A1SMN1; SMN2MEN1KMT2A
SCHEMBL2311046 0.74 DAO (0.50) DAOALDH1A1HPGDMAPTSMN1; SMN2
SCHEMBL13015480 0.74 DAO (0.66) DAOALDH1A1LMNAMEN1KMT2A
SCHEMBL20715436 0.72 LMNA (0.61) DAOALDH1A1HPGDMAPTSMN1; SMN2
SCHEMBL14325098 0.72 DAO (0.48) DAOALDH1A1HPGDMAPTSMN1; SMN2
SCHEMBL23997181 0.69 PRNP (0.53) DAOALDH1A1MAPTSMN1; SMN2LMNA
SCHEMBL30345145 0.69 PRNP (0.53) DAOALDH1A1MAPTSMN1; SMN2LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8138177-B2 Benzimidazolone derivatives as CB2 receptor ligands PFIZER INC. (US) 2012-03-20 US disclosed
EP-1861377-B1 BENZIMIDAZOLONE DERIVATIVES AS CB2 RECEPTOR LIGANDS PFIZER (US) 2010-12-29 EP disclosed
US-20090298811-A1 BENZIMIDAZOLONE DERIVATIVES PFIZER INC 2009-12-03 US disclosed
EP-2114897-A2 BENZIMIDAZOLONE DERIVATIVES Pfizer Products Inc. (US) 2009-11-11 EP disclosed
US-20090181957-A1 BENZIMIDAZOLONE DERIVATIVES AS CB2 RECEPTOR LIGANDS ANDO KAZUO 2009-07-16 US disclosed
WO-2008032164-A2 BENZIMIDAZOLONE DERIVATIVES PFIZER PRODUCTS INC. (US) 2008-03-20 WO disclosed
WO-2008032164-A2 BENZIMIDAZOLONE DERIVATIVES PFIZER PRODUCTS INC. (US) 2008-03-20 WO disclosed
EP-1861377-A1 BENZIMIDAZOLONE DERIVATIVES AS CB2 RECEPTOR LIGANDS Pfizer, Inc. (US) 2007-12-05 EP disclosed
WO-2006097808-A1 BENZIMIDAZOLONE DERIVATIVES AS CB2 RECEPTOR LIGANDS PFIZER JAPAN INC. (JP) 2006-09-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090298811-A1 BENZIMIDAZOLONE DERIVATIVES TRPV1, CNR1, CNR2 DAO 4401/4885ALDH1A1 2502/4885HPGD 3516/4885
US-20090181957-A1 BENZIMIDAZOLONE DERIVATIVES AS CB2 RECEPTOR LIGANDS TRPV1, CNR1, CNR2 DAO 4549/4885ALDH1A1 2949/4885HPGD 3445/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.